您的位置: 首页 > 2025年1月 第56卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

Ki-67、MCM2、p16在宫颈鳞状上皮内病变中表达及意义

Analysis of the expression and significance of Ki-67、MCM2 and p16 in cervical intraepithelial lesions

来源期刊: 广州医药 | 82-88 发布时间:2025-02-13 收稿时间:2025/11/13 18:56:13 阅读量:21
作者:
关键词:
宫颈鳞状上皮内病变Ki-67微小染色体维持蛋白2p16
cervical intraepithelial lesionsKi-67MCM2p16
DOI:
10.20223/j.cnki.1000-8535.2025.01.012
收稿时间:
2024-02-21 
修订日期:
 
接收日期:
 
引用总数:
1  
目的 探讨Ki-67、微小染色体维持蛋白2(MCM2)、p16在宫颈鳞状上皮内病变中的表达及其临床意义。方法 采用免疫组化检测Ki-67、MCM2、p16在宫颈炎症组14例、低级别鳞状上皮内病变(LSIL)组47例、高级别鳞状上皮内病变(HSIL)组49例中的表达情况,以病理结果作为金标准,对结果进行统计分析。结果 HSIL组中Ki-67、MCM2、p16阳性率均高于炎症组和LSIL组(均P<0.017)。HSIL组中Ki-67、MCM2过表达率均显著高于炎症组和LSIL组(均P<0.017)。随着宫颈病变级别增加,Ki-67及MCM2阳性范围从基底层至表层逐渐扩大。MCM2及Ki-67在LSIL组中表达模式多为基底层的非过表达模式,HSIL组多为中层及以上的过表达模式。Spearman相关性分析显示,MCM2和Ki-67在宫颈鳞状上皮内病变中的表达强度之间呈正相关(r=0.801,P<0.05);p16与MCM2在宫颈鳞状上皮内病变中的表达呈正相关(r=0.559,P<0.05);p16与Ki-67在宫颈鳞状上皮内病变中的表达呈正相关(r=0.478,P<0.05)。结论 p16阳性提示宫颈高级别鳞状上皮内病变。MCM2与Ki-67在宫颈鳞状上皮内病变中的表达具有较高一致性,MCM2可作为宫颈鳞状上皮内病变新的增殖标志物。
Objective To investigate the expression and significance of Ki-67,MCM2 and p16 in cervical intraepithelial lesions.Methods The expressions of Ki-67,MCM2 and p16 in cervicitis group(14 cases),low-grade squamous intraepithelial lesion(LSIL) group(47 cases)and high-grade squamous intraepithelial lesion(HSIL) group(49 cases)were detected by immunohistochemistry.The pathological results were used as the gold standard for statistical analysis.Results The positive rates of Ki-67,MCM2 and p16 in HSIL group were significantly higher than those in cervicitis group and LSIL group(P<0.017).The over-expression rates of Ki-67,MCM2 in HSIL group were significantly higher than those in cervicitis group and LSIL group(P<0.017).With the increase of cervical lesion grade,the positive range of Ki-67 and MCM2 gradually expanded from basal layer to surface layer.The expression patterns of MCM2 and Ki-67 in LSIL group were mostly non-overexpressed in the basal layers,while those in HSIL group were mostly overexpressed in the middle layer and above.Spearman correlation analysis showed that the expression intensity of MCM2 and Ki-67 in cervical squamous intraepithelial lesions was positively correlated(r=0.801,P<0.05).There was a positive correlation between the expression of p16 and MCM2 in cervical squamous intraepithelial lesions(r=0.559,P<0.05).There was a positive correlation between the expression of p16 and Ki-67 in cervical squamous intraepithelial lesions(r=0.478,P<0.05).Conclusions Positive p16 indicates high-grade squamous intraepithelial lesion.The expression of MCM2 and Ki-67 in cervical intraepithelial lesions is highly consistent.MCM2 can be used as a new proliferative marker for cervical intraepithelial lesions.
1、 ZHENG J.Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection[J].Int J Clin Exp Pathol,2015,8(1):875-880. ZHENG J.Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection[J].Int J Clin Exp Pathol,2015,8(1):875-880.
2、 GUTIéRREZ-HOYA A,SOTO-CRUZ I.Role of the JAK/STAT Pathway in Cervical Cancer:Its Relationship with HPV E6/E7 Oncoproteins[J].Cells,2020,9(10). GUTIéRREZ-HOYA A,SOTO-CRUZ I.Role of the JAK/STAT Pathway in Cervical Cancer:Its Relationship with HPV E6/E7 Oncoproteins[J].Cells,2020,9(10).
3、 DERBIE A,MEKONNEN D,WOLDEAMANUEL Y,et al.HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia(CIN2+):A systematic review[J].Infect Agent Cancer,2020(15):9. DERBIE A,MEKONNEN D,WOLDEAMANUEL Y,et al.HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia(CIN2+):A systematic review[J].Infect Agent Cancer,2020(15):9.
4、 王登山,曹磊,钱金林等.HPVL1壳蛋白联合MCM2检测对HPV DNA阳性患者宫颈病变的诊断及预后意义[J].现代肿瘤医学,2020,28(2):287-292. 王登山,曹磊,钱金林等.HPVL1壳蛋白联合MCM2检测对HPV DNA阳性患者宫颈病变的诊断及预后意义[J].现代肿瘤医学,2020,28(2):287-292.
5、 张仁超,李镔薇,赵东晖等.联合检测P16及Ki67在宫颈鳞状上皮内病变中的表达及临床意义[J].现代诊断与治疗,2023,34(6):879-881. 张仁超,李镔薇,赵东晖等.联合检测P16及Ki67在宫颈鳞状上皮内病变中的表达及临床意义[J].现代诊断与治疗,2023,34(6):879-881.
6、 SWAIN S,NISHAT R,RAMACHANDRAN S,et al.Comparative evaluation of immunohistochemical expression of MCM2 and Ki67 in oral epithelial dysplasia and oral squamous cell carcinoma[J].J Cancer Res Ther,2022,18(4):997-1002. SWAIN S,NISHAT R,RAMACHANDRAN S,et al.Comparative evaluation of immunohistochemical expression of MCM2 and Ki67 in oral epithelial dysplasia and oral squamous cell carcinoma[J].J Cancer Res Ther,2022,18(4):997-1002.
7、 ACHARYA S,ARNOLD D,PRABHU P,et al.MCM-2 an alternative to Ki-67 for assessing cell proliferation in odontogenic pathologies[J].J Oral Med Pathol,2019,31(1):52-58. ACHARYA S,ARNOLD D,PRABHU P,et al.MCM-2 an alternative to Ki-67 for assessing cell proliferation in odontogenic pathologies[J].J Oral Med Pathol,2019,31(1):52-58.
8、 MENON S S,GURUVAYOORAPPAN C,SAKTHIVEL K M,et al.Ki-67 protein as a tumour proliferation marker[J].Clin Chim Acta,2019,491:39-45. MENON S S,GURUVAYOORAPPAN C,SAKTHIVEL K M,et al.Ki-67 protein as a tumour proliferation marker[J].Clin Chim Acta,2019,491:39-45.
9、 üNAL ?,?ZMEN T,?LGüN A S,et al.MCM-2 levels as a potential biomarker for predicting high-risk breast cancer patients according to TAILORx classification[J].Breast Cancer(Dove Med Press),2023(15):659-669. üNAL ?,?ZMEN T,?LGüN A S,et al.MCM-2 levels as a potential biomarker for predicting high-risk breast cancer patients according to TAILORx classification[J].Breast Cancer(Dove Med Press),2023(15):659-669.
10、 VIVATVAKIN S,RATCHATASWAN T,LEESUTIPORNCHAI T,et al.MCM-2,Ki-67,and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma[J].Sci Rep,2021,11(1):14607. VIVATVAKIN S,RATCHATASWAN T,LEESUTIPORNCHAI T,et al.MCM-2,Ki-67,and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma[J].Sci Rep,2021,11(1):14607.
11、 HSU E C,SHEN M,ASLAN M,et al.MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer[J].Sci Rep,2021,11(1):13305. HSU E C,SHEN M,ASLAN M,et al.MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer[J].Sci Rep,2021,11(1):13305.
12、 GUO F,KONG W N,FENG Y C,et al.Comprehensive analysis of the expression and prognosis for MCMs in human gastric cancer[J].Technol Cancer Res Treat,2020(19):1533033820970688. GUO F,KONG W N,FENG Y C,et al.Comprehensive analysis of the expression and prognosis for MCMs in human gastric cancer[J].Technol Cancer Res Treat,2020(19):1533033820970688.
13、 World Health Organization.Female genital tumours. IARC.WHO classification of tumours.5th Edition[EB/OL].[2021-01-25].https://tumourclassification.iarc.who.int/9789283245049. World Health Organization.Female genital tumours. IARC.WHO classification of tumours.5th Edition[EB/OL].[2021-01-25].https://tumourclassification.iarc.who.int/9789283245049.
14、 蒋莉萍,吴凤珍,肖艳,等.p16、微型染色体维持蛋白2、Ki-67在宫颈鳞状上皮内病变的表达与意义[J].现代医学与健康研究电子杂志,2021,5(17):35-38. 蒋莉萍,吴凤珍,肖艳,等.p16、微型染色体维持蛋白2、Ki-67在宫颈鳞状上皮内病变的表达与意义[J].现代医学与健康研究电子杂志,2021,5(17):35-38.
15、 DA MATA S,FERREIRA J,NICOLáS I,et al.P16 and HPV genotype significance in HPV-associated cervical cancer-a large cohort of two tertiary referral centers[J].Int J Mol Sci,2021,22(5). DA MATA S,FERREIRA J,NICOLáS I,et al.P16 and HPV genotype significance in HPV-associated cervical cancer-a large cohort of two tertiary referral centers[J].Int J Mol Sci,2021,22(5).
16、 游伟强,王莉平,吴小延,等.p16和HPV DNA检测在ASC-US分流中的价值研究[J].广州医药,2022,53(4):30-35,41. 游伟强,王莉平,吴小延,等.p16和HPV DNA检测在ASC-US分流中的价值研究[J].广州医药,2022,53(4):30-35,41.
17、 EBISCH R M F,RIJSTENBERG L L,SOLTANI G G,et al.Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population[J].Acta Obstet Gynecol Scand,2022,101(11):1328-1336. EBISCH R M F,RIJSTENBERG L L,SOLTANI G G,et al.Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population[J].Acta Obstet Gynecol Scand,2022,101(11):1328-1336.
18、 ESTêV?O D,COSTA N R,GIL DA COSTA R M,et al.Hallmarks of HPV carcinogenesis:The role of E6,E7 and E5 oncoproteins in cellular malignancy[J].Biochim Biophys Acta Gene Regul Mech,2019,1862(2):153-162. ESTêV?O D,COSTA N R,GIL DA COSTA R M,et al.Hallmarks of HPV carcinogenesis:The role of E6,E7 and E5 oncoproteins in cellular malignancy[J].Biochim Biophys Acta Gene Regul Mech,2019,1862(2):153-162.
19、 武振宇. HPVE6/E7 mRNA和HPV-DNA检测在宫颈癌筛查中的价值[J].川北医学院学报,2022,37(10):1313-1316. 武振宇. HPVE6/E7 mRNA和HPV-DNA检测在宫颈癌筛查中的价值[J].川北医学院学报,2022,37(10):1313-1316.
20、 SHI Q,XU L,YANG R,et al.Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions[J].Oncol Lett,2019,18(2):1351-1355. SHI Q,XU L,YANG R,et al.Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions[J].Oncol Lett,2019,18(2):1351-1355.
21、 AUNG T N,ACS B,WARRELL J,et al.A new tool for technical standardization of the Ki67 immunohistochemical assay[J].Mod Pathol,2021,34(7):1261-1270. AUNG T N,ACS B,WARRELL J,et al.A new tool for technical standardization of the Ki67 immunohistochemical assay[J].Mod Pathol,2021,34(7):1261-1270.
22、 SAMAD A,HAQUE F,NAIN Z,et al.Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer[J].Heliyon,2020,6(10):e05087. SAMAD A,HAQUE F,NAIN Z,et al.Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer[J].Heliyon,2020,6(10):e05087.
23、 ISSAC M S M,YOUSEF E,TAHIR M R,et al.MCM2,MCM4,and MCM6 in breast cancer:Clinical utility in diagnosis and prognosis[J].Neoplasia,2019,21(10):1015-1035. ISSAC M S M,YOUSEF E,TAHIR M R,et al.MCM2,MCM4,and MCM6 in breast cancer:Clinical utility in diagnosis and prognosis[J].Neoplasia,2019,21(10):1015-1035.
24、 SERRA S,CHETTY R.p16:Gene of the Month[J].J Clin Pathol,2018,71(10):853-858. SERRA S,CHETTY R.p16:Gene of the Month[J].J Clin Pathol,2018,71(10):853-858.
25、 邱丽华,陈飞,赵卫东,等.2024子宫颈癌筛查和早期精准诊断现状白皮书[J].中国实用妇科与产科杂志,2024,40(1):85-95. 邱丽华,陈飞,赵卫东,等.2024子宫颈癌筛查和早期精准诊断现状白皮书[J].中国实用妇科与产科杂志,2024,40(1):85-95.
26、 SINGH D,VIGNAT J,LORENZONI V,et al.Global estimates of incidence and mortality of cervical cancer in 2020:A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative[J].Lancet Glob Health,2023,11(2):e197-e206. SINGH D,VIGNAT J,LORENZONI V,et al.Global estimates of incidence and mortality of cervical cancer in 2020:A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative[J].Lancet Glob Health,2023,11(2):e197-e206.
1、易丹妮,郭芝亮,蔡春芳,等.CO2激光在宫颈上皮内瘤变Ⅱ级中的疗效[J].广州医药,2025,56(09):1288-1295.DOI:10.20223/j.cnki.1000-8535.2025.09.019. 易丹妮,郭芝亮,蔡春芳,等.CO2激光在宫颈上皮内瘤变Ⅱ级中的疗效[J].广州医药,2025,56(09):1288-1295.DOI:10.20223/j.cnki.1000-8535.2025.09.019.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录